215 related articles for article (PubMed ID: 37505931)
1. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan.
Chandler C; Burnett H; Schaible K; Senthil V; Kato M; Miura Y; Osawa T; Uemura H; Kuwabara H
J Med Econ; 2023; 26(1):1009-1018. PubMed ID: 37505931
[TBL] [Abstract][Full Text] [Related]
2. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
[TBL] [Abstract][Full Text] [Related]
3. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England.
Meng J; Lister J; Vataire AL; Casciano R; Dinet J
Clinicoecon Outcomes Res; 2018; 10():243-250. PubMed ID: 29719414
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Dhanji N; Decimoni TC; Dyer MTD; May JR; van de Wetering G; Petersohn S; Nickel K; Silva A; Muniz DQB; Casagrande D Oliveira AP
J Med Econ; 2023; 26(1):1108-1121. PubMed ID: 37632452
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084
[TBL] [Abstract][Full Text] [Related]
7. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
[TBL] [Abstract][Full Text] [Related]
8. Treatment sequences for advanced renal cell carcinoma: A health economic assessment.
Deniz B; Ambavane A; Yang S; Altincatal A; Doan J; Rao S; Michaelson MD
PLoS One; 2019; 14(8):e0215761. PubMed ID: 31465470
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
[TBL] [Abstract][Full Text] [Related]
11. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
[TBL] [Abstract][Full Text] [Related]
12. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma.
Liu R; Qiu K; Wu J; Jiang Y; Wu P; Pang J
Immunotherapy; 2022 Aug; 14(11):859-869. PubMed ID: 35754404
[TBL] [Abstract][Full Text] [Related]
14. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm.
Bamias A; Zakopoulou R; Tzannis K; Sakellakis M; Koutsoukos K; Kyriazoglou A; Panagiotou A; Armylagos S; Rokas K; Gotzias D; Boulouta A; Bozionelou V; Stravodimos K; Varkarakis I; Mavroudis D; Dimopoulos MA
Anticancer Drugs; 2023 Mar; 34(3):413-421. PubMed ID: 36730619
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.
Karner C; Kew K; Wakefield V; Masento N; Edwards SJ
BMJ Open; 2019 Mar; 9(3):e024691. PubMed ID: 30826762
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
[TBL] [Abstract][Full Text] [Related]
17. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
Perrin A; Sherman S; Pal S; Chua A; Gorritz M; Liu Z; Wang X; Culver K; Casciano R; Garrison LP
J Med Econ; 2015 Mar; 18(3):200-9. PubMed ID: 25422989
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea.
Kim S; Han S; Kim H; Suh HS
Appl Health Econ Health Policy; 2021 Jul; 19(4):545-555. PubMed ID: 33651367
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Amzal B; Fu S; Meng J; Lister J; Karcher H
PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.
Liao W; Lei W; Feng M; Yang Y; Wu Q; Zhou K; Bai L; Wen F; Li Q
Adv Ther; 2021 Dec; 38(12):5662-5670. PubMed ID: 34664194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]